1. Home
  2. CHRS vs UNB Comparison

CHRS vs UNB Comparison

Compare CHRS & UNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • UNB
  • Stock Information
  • Founded
  • CHRS 2010
  • UNB 1891
  • Country
  • CHRS United States
  • UNB United States
  • Employees
  • CHRS N/A
  • UNB N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • UNB Major Banks
  • Sector
  • CHRS Health Care
  • UNB Finance
  • Exchange
  • CHRS Nasdaq
  • UNB Nasdaq
  • Market Cap
  • CHRS 185.5M
  • UNB 167.6M
  • IPO Year
  • CHRS 2014
  • UNB 1998
  • Fundamental
  • Price
  • CHRS $1.52
  • UNB $31.26
  • Analyst Decision
  • CHRS Strong Buy
  • UNB
  • Analyst Count
  • CHRS 4
  • UNB 0
  • Target Price
  • CHRS $5.38
  • UNB N/A
  • AVG Volume (30 Days)
  • CHRS 10.1M
  • UNB 11.3K
  • Earning Date
  • CHRS 11-06-2024
  • UNB 01-15-2025
  • Dividend Yield
  • CHRS N/A
  • UNB 4.57%
  • EPS Growth
  • CHRS N/A
  • UNB N/A
  • EPS
  • CHRS N/A
  • UNB 1.94
  • Revenue
  • CHRS $304,340,000.00
  • UNB $46,385,000.00
  • Revenue This Year
  • CHRS $1.64
  • UNB N/A
  • Revenue Next Year
  • CHRS $16.98
  • UNB N/A
  • P/E Ratio
  • CHRS N/A
  • UNB $16.24
  • Revenue Growth
  • CHRS 44.19
  • UNB N/A
  • 52 Week Low
  • CHRS $0.66
  • UNB $21.00
  • 52 Week High
  • CHRS $3.70
  • UNB $37.70
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 52.47
  • UNB 49.29
  • Support Level
  • CHRS $1.45
  • UNB $31.00
  • Resistance Level
  • CHRS $1.85
  • UNB $35.98
  • Average True Range (ATR)
  • CHRS 0.23
  • UNB 1.44
  • MACD
  • CHRS -0.03
  • UNB -0.54
  • Stochastic Oscillator
  • CHRS 3.88
  • UNB 29.85

About CHRS Coherus BioSciences Inc.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

About UNB Union Bankshares Inc.

Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group. Geographically, all the business activity is functioned through the United States.

Share on Social Networks: